Cyp3a Inducers + Paltusotine Interaction
Moderateinteraction on record
Description
Concomitant use may decrease paltusotine exposure and affect therapeutic response. May require PALSONIFY dosage increase up to three-fold or 120 mg daily, whichever is less.
Mechanism
CYP3A4 induction decreases paltusotine exposure
Source: NLP:paltusotine